Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.34 |
| ▸ | GBA1 | P04062 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.31 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.31 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.31 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083286 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL5594313 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL15145344 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL3748632 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL13969566 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL24246852 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL7772022 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL22640981 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL21479622 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL14339490 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143818-A | Compounds, conjugates and uses thereof for targeted delivery of oligonucleotide drugs | 广州必贝特医药股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| EP-4743120-A1 | MOLECULAR DEGRADERS FOR THE TREATMENT OF IGA NEPHROPATHY | Biohaven Therapeutics Ltd. (VG) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025122525-A1 | MOLECULAR DEGRADERS OF ANTI-β1ECII AUTO-ANTIBODIES | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025035052-A1 | MOLECULAR DEGRADERS FOR THE TREATMENT OF IGA NEPHROPATHY | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-13 | — | — | WO | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023178199-A2 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023006909-A1 | FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE | THE UNIVERSITY OF MANCHESTER (GB) | 2023-02-02 | — | — | WO | disclosed |
| WO-2021081420-A2 | CONJUGATES AND METHODS FOR TREATING ACROMEGALY | GENEVANT SCIENCES GMBH (CH) | 2021-04-29 | — | — | WO | disclosed |
| WO-2020191207-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-09-24 | — | — | WO | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
| EP-1544208-B1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2010-05-26 | — | — | EP | disclosed |
| EP-1115731-A2 | NOVEL PYRANOSES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000014097-A2 | NOVEL PYRANOSES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-16 | — | — | WO | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | GBA2 228/4885LGALS3 240/4885GBA1 150/4885 |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | GBA2 129/4885LGALS3 328/4885GBA1 78/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | GBA2 1269/4885LGALS3 435/4885GBA1 1063/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | GBA2 35/4885LGALS3 264/4885GBA1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.